Clinical Trial: Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07422857) titled 'Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function' on Jan. 29.

Brief Summary: This study is to evaluate the efficacy and safety of [18F]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.

Study Start Date: Jan. 22

Study Type: INTERVENTIONAL

Condition: Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

Intervention: DRUG: [18F]-APN-1607

Participants will receive a single intravenous injection of 5-7 mCi of [18F]-APN-1607, and a whole-body PET/CT scan will begin immediately after ad...